Treatment
Cytokine-induced Killer Cells clinical trials
We’re tracking 6 recruiting studies that include Cytokine-induced Killer Cells, each written for real people, not researchers, below.
Recruiting studies
- NCT07635056RecruitingPhase 2
Natural killer cells for hard-to-treat neuroblastoma
This trial tests specially prepared immune cells (called CIML-NK cells) from a partially matched family donor to fight neuroblastoma that has returned or stopped responding to standard treatment. The goal is to see if these cells can help patients whose cancer is difficult to control.
Cincinnati, OhioAges 1–39 - NCT01898663RecruitingPhase 1/Phase 2
Vaccine plus immune cell therapy for adults with AML
This early-phase study tests a combined treatment—an immune “DC” vaccine plus specially trained killer immune cells—for adults with AML. The goal is to see if this approach is safe and can help control the disease.
BeijingAges 18 years+ - NCT05580601RecruitingPhase 1/Phase 2
Immunotherapy trial for children with relapsed or stubborn AML
This Phase 1/2 trial tests a lab-made immune-cell treatment (NK cells) for children with acute myeloid leukemia (AML) that has come back or did not respond to treatment. It aims to help the immune system attack leukemia cells in the bone marrow, especially when standard treatments have not worked.
Cincinnati, OhioAges 2 years+ - NCT05629546RecruitingPhase 1
Nivolumab and relatlimab with lab-made memory NK cells
This Phase 1 study tests a new form of immune cells (NK cells) along with nivolumab and relatlimab for advanced melanoma that has worsened after prior PD-1/PD-L1 treatments. It may help your body recognize and attack melanoma cells more strongly.
St Louis, MissouriAges 18 years+ - NCT06152809RecruitingPhase 1
NK cell therapy plus venetoclax for high-risk AML
This trial tests an experimental NK cell therapy (CIML NK cells) given together with venetoclax for people with AML that has high-risk features or is not fully cleared by current treatment. It aims to stop the leukemia from coming back.
Boston, MassachusettsAges 18 years+ - NCT06321484RecruitingPhase 1
NK cell therapy for recurrent platinum-resistant ovarian cancer
This trial tests a new type of immune cell therapy (CIML NK cells) given directly into the abdomen for women with ovarian cancer that has come back and is now resistant to standard platinum chemotherapy. The goal is to see if these specially trained cells can fight the cancer safely.
Boston, MassachusettsAges 18–85
What Cytokine-induced Killer Cells is being studied for
Conditions with recruiting Cytokine-induced Killer Cells studies.
Common questions
- Are there clinical trials studying Cytokine-induced Killer Cells?
- Yes. Clin2 currently lists 6 recruiting studies that include Cytokine-induced Killer Cells, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cytokine-induced Killer Cells trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cytokine-induced Killer Cells an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cytokine-induced Killer Cells or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.